Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti-CD137 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 0.1 mg/kg every 3 weeks |
| Arm 2 | ACTIVE_COMPARATOR | 1 mg/kg every 3 weeks |
| Arm 3 | ACTIVE_COMPARATOR | 1 mg/kg every 6 weeks |
| Arm 4 | ACTIVE_COMPARATOR | 5 mg/kg every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Anti-CD137 (4-1BB) (BMS-663513) | DRUG | IV solution, IV, until PD or toxicity |
Inclusion Criteria: * Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvan...
Top 20 of 51 competitors
Anti-CD137 is an investigational oncology therapy being studied for the treatment of melanoma. It is currently in Phase 2 clinical development as a monotherapy for second-line melanoma. The drug is being developed by Bristol-Myers Squibb Company (BMY).
Anti-CD137 targets the CD137 receptor, which is a costimulatory molecule involved in the activation of immune cells such as T cells. By targeting CD137, the drug aims to enhance the immune system's ability to fight cancer cells. This mechanism is being evaluated in the context of melanoma treatment.
Anti-CD137 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with melanoma.
Anti-CD137 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing clinical program includes a completed Phase 2 trial that enrolled 158 participants with melanoma.
Anti-CD137 is being studied in a Phase 2 clinical trial with the identifier NCT00612664. This trial, titled 'Phase II, 2nd Line Melanoma - RAND Monotherapy,' was a randomized, active-controlled study that has been completed. It enrolled 158 participants across multiple countries, including the United States, Canada, Denmark, France, Germany, and Italy.